Surgery Partners, Inc. (SGRY) Social Stream
SURGERY PARTNERS INC (SGRY) Price Targets From Analysts
Use the tables below to see what analysts covering SURGERY PARTNERS INC think about its future price and what recommendations they have for investors and traders.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-04 | 7 | $78 | $50 | $61.125 | $31.13 | 96.35% |
| 2021-11-09 | 7 | $78.001 | $50 | $61.125 | $31.13 | 96.35% |
| 2021-11-29 | 7 | $78.001 | $50 | $61.125 | $31.13 | 96.35% |
| 2021-11-30 | 8 | $78.001 | $50 | $62.444 | $31.13 | 100.59% |
| 2021-12-03 | 8 | $78.001 | $50 | $63.444 | $31.13 | 103.8% |
| 2021-12-08 | 8 | $78 | $50 | $62.222 | $31.13 | 99.88% |
| 2022-01-07 | 8 | $75 | $50 | $61.333 | $31.13 | 97.02% |
| 2022-01-10 | 9 | $75 | $50 | $62.111 | $31.13 | 99.52% |
| 2022-01-25 | 9 | $75 | $50 | $62.333 | $31.13 | 100.23% |
| 2022-03-01 | 9 | $75 | $50 | $63.111 | $31.13 | 102.73% |
| 2022-05-03 | 9 | $75 | $55 | $63.888 | $31.13 | 105.23% |
| 2022-05-04 | 9 | $75 | $55 | $66 | $31.13 | 112.01% |
| 2022-05-10 | 9 | $75 | $57 | $66.222 | $31.13 | 112.73% |
| 2022-06-14 | 9 | $75 | $55 | $64.555 | $31.13 | 107.37% |
| 2022-06-15 | 9 | $75 | $36 | $62.444 | $31.13 | 100.59% |
| 2022-08-02 | 9 | $75 | $42 | $63.111 | $31.13 | 102.73% |
| 2022-08-03 | 9 | $75 | $42 | $61.333 | $31.13 | 97.02% |
| 2022-08-05 | 10 | $75 | $39 | $59.3 | $31.13 | 90.49% |
| 2022-08-13 | 9 | $75 | $39 | $59.3 | $31.13 | 90.49% |
| 2022-09-21 | 9 | $75 | $34 | $58.5 | $31.13 | 87.92% |
| 2022-11-09 | 7 | $75 | $30 | $55.5 | $31.13 | 78.28% |
| 2022-11-10 | 10 | $73 | $30 | $53.1 | $31.13 | 70.58% |
| 2022-11-15 | 10 | $73 | $30 | $52.7 | $31.13 | 69.29% |
| 2022-11-22 | 10 | $73 | $30 | $50.4 | $31.13 | 61.9% |
| 2022-11-23 | 10 | $73 | $30 | $49.4 | $31.13 | 58.69% |
| 2022-12-05 | 9 | $65 | $30 | $42.666 | $31.13 | 37.06% |
| 2023-02-08 | 9 | $65 | $34 | $43.111 | $31.13 | 38.49% |
| 2023-02-13 | 9 | $65 | $35 | $43.333 | $31.13 | 39.2% |
| 2023-03-06 | 9 | $65 | $35 | $43.666 | $31.13 | 40.27% |
The Trend in the Analyst Price Target
Over the past 34 months, SGRY's average price target has gone up $29.27.
SGRY reports an average of 68.33% for its upside potential over the past 44 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-05-04 | 9 | 75 | 55 | 66.000 | 56.95 | 15.89% |
| 2022-05-27 | 9 | 75 | 55 | 64.555 | 40.24 | 60.42% |
| 2022-09-17 | 9 | 75 | 34 | 58.500 | 27.51 | 112.65% |
| 2022-11-23 | 9 | 73 | 30 | 48.200 | 27.49 | 75.34% |
| 2023-01-26 | 9 | 65 | 34 | 43.111 | 32.36 | 33.22% |
SGRY Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.78 | 5 | 1 | 3 | 0 | 0 | 9 |
The Trend in the Broker Recommendations
Over the past 52 weeks, SGRY's average broker recommendation rating worsened by 0.34.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- In terms of how SURGERY PARTNERS INC fares relative to all US stocks, note that its variance in analysts' estimates is lower than -2197.11% of that group.
- SURGERY PARTNERS INC's upside potential (average analyst target price relative to current price) is greater than 2433.75% of all US stocks.
- In terms of how SURGERY PARTNERS INC fares relative to stocks in the mid market cap category, note that its average analyst price target is higher than 2386.48% of that group.
- SURGERY PARTNERS INC's number of analysts covering the stock is greater than 2340.13% of stocks in the mid market cap category.
In terms of price targets and recommendations offered by analysts, the stocks in the Healthcare industry with the ratings most similar to SURGERY PARTNERS INC are CYH, ACHC, and BKD.
View All Top Stocks by Price Target
What is the outlook for SGRY? Use POWR Ratings for clearer insight into price direction.